{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T12:57:37Z","timestamp":1781614657204,"version":"3.54.5"},"reference-count":68,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T00:00:00Z","timestamp":1760918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T00:00:00Z","timestamp":1760918400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharmacol. Rep"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Taxol (Tx) is widely used in cancer therapy due to its ability to disrupt microtubule dynamics, inhibiting cell division and tumor proliferation. However, multidrug resistance (MDR) mechanisms, including enhanced drug efflux, altered metabolism, mutations in tubulin, and inhibition of apoptosis, challenge its efficacy. Peptide-based therapies have emerged as promising and significant solutions to overcome Tx resistance. These peptides offer high specificity, lower toxicity, and acceptable cell membrane penetration, enhancing precision medicine capabilities. Recent advancements focus on peptides that modulate drug efflux, stabilize microtubules, and promote apoptosis in cancer cells. The ATP synthase (ATP)-binding cassette transporters (ABC) transporter ABCB1, tubulin subunits, and anti-apoptotic proteins such as Bcl-2 show potential in restoring Tx effectiveness against MDR. Combining peptides with nanoparticle delivery systems improves tumor penetration and reduces side effects. Despite challenges like protease degradation and immunogenicity, peptide treatment addresses limitations. Peptide cancer therapies could revolutionize anticancer treatment by providing targeted, less toxic alternatives, especially for MDR. phenotype.<\/jats:p>","DOI":"10.1007\/s43440-025-00795-6","type":"journal-article","created":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T03:04:05Z","timestamp":1760929445000},"page":"1627-1638","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Peptide-based strategies for overcoming taxol-resistance in cancer therapy \u2013 a narrative review"],"prefix":"10.1007","volume":"77","author":[{"given":"Angelika","family":"D\u0142ugosz-Pokorska","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarzyna","family":"Gach-Janczak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,20]]},"reference":[{"key":"795_CR1","doi-asserted-by":"crossref","unstructured":"Gallego-Jara J, Lozano-Terol G, Sola-Mart\u00ednez RA, C\u00e1novas-D\u00edaz M, de Diego Puente T. A compressive review about Taxol\u00ae: history and future challenges. Molecules. 2020;25:5986.","DOI":"10.3390\/molecules25245986"},{"key":"795_CR2","doi-asserted-by":"crossref","unstructured":"Orr GA, Verdier-Pinard P, McDaid H, Horwitz SB. Mechanisms of taxol resistance related to microtubules. Oncogene. 2003;22:7280\u201395.","DOI":"10.1038\/sj.onc.1206934"},{"key":"795_CR3","doi-asserted-by":"crossref","unstructured":"Luo X, Teng QX, Dong JY, Lin F, Ohnuma SKato Y, et al. Antimicrobial peptide reverses ABCB1-mediated chemotherapeutic drug resistance. Front Pharmacol. 2020;11:1208.","DOI":"10.3389\/fphar.2020.01208"},{"key":"795_CR4","doi-asserted-by":"crossref","unstructured":"Nh\u00e0n NTT, Yamada T, Yamada KH. Peptide-based agents for cancer treatment: current applications and future directions. Int J Mol Sci. 2023;24:12931.","DOI":"10.3390\/ijms241612931"},{"key":"795_CR5","doi-asserted-by":"crossref","unstructured":"Holz E, Darwish M, Tesar DB, Shatz-Binder W. A review of protein- and peptide-based chemical conjugates: past, present, and future. Pharmaceutics. 2023;15:600.","DOI":"10.3390\/pharmaceutics15020600"},{"key":"795_CR6","doi-asserted-by":"crossref","unstructured":"Rowinsky EK, Donehower RC. Paclitaxel (Taxol). N Engl J Med. 1995;332:1004\u201314.","DOI":"10.1056\/NEJM199504133321507"},{"key":"795_CR7","unstructured":"Rowinsky EK, Eisenhauer EA, Chaudhry V, Arbuck SG, Donehower RC. Clinical toxicities encountered with paclitaxel (taxol). Semin Oncol. 1993;20(Suppl 3):1\u201315."},{"key":"795_CR8","doi-asserted-by":"crossref","unstructured":"Manfredi JJ, Horwitz SB. Vinblastine paracrystals from cultured cells are calcium-stable. Exp Cell Res. 1984;150:205\u201312.","DOI":"10.1016\/0014-4827(84)90715-8"},{"key":"795_CR9","doi-asserted-by":"crossref","unstructured":"Downing KH, Nogales E. Cryoelectron microscopy applications in the study of tubulin structure, microtubule architecture, dynamics, and assemblies, and interaction of microtubules with motors. Methods Enzymol. 2010;483:121\u201342.","DOI":"10.1016\/S0076-6879(10)83006-X"},{"key":"795_CR10","doi-asserted-by":"crossref","unstructured":"Shi X, Sun X. Regulation of paclitaxel activity by microtubule-associated proteins in cancer chemotherapy. Cancer Chemother Pharmacol. 2017;80:909\u201317.","DOI":"10.1007\/s00280-017-3398-2"},{"key":"795_CR11","doi-asserted-by":"crossref","unstructured":"Zhao S, Tang Y, Wang R, Najafi M. Mechanisms of cancer cell death induction by paclitaxel: an updated review. Apoptosis. 2022;27:647\u201367.","DOI":"10.1007\/s10495-022-01750-z"},{"key":"795_CR12","doi-asserted-by":"crossref","unstructured":"Foland TB, Dentler WL, Suprenant KA, Gupta ML. Paclitaxel-induced microtubule stabilization causes mitotic block and apoptotic-like cell death in a paclitaxel-sensitive strain of saccharomyces cerevisiae. Yeast. 2005;22:971\u201378.","DOI":"10.1002\/yea.1284"},{"key":"795_CR13","unstructured":"Priyadarshini K, Keerthi AU. Paclitaxel against cancer: a short review. Med Chem. 2012;2:139\u201341."},{"key":"795_CR14","doi-asserted-by":"crossref","unstructured":"Edwardson D, Chewchuk S, Parissenti AM. Resistance to anthracyclines and taxanes in breast cancer. In: Breast cancer metastasis and drug resistance: progress and prospects. Springer; 2013. p. 227\u201347.","DOI":"10.1007\/978-1-4614-5647-6_13"},{"key":"795_CR15","doi-asserted-by":"crossref","unstructured":"Stanton RA, Gernert KM, Nettles JH, Aneja R. Drugs that target dynamic microtubules: a new molecular perspective. Med Res Rev. 2011;31:443\u201381.","DOI":"10.1002\/med.20242"},{"key":"795_CR16","doi-asserted-by":"crossref","unstructured":"Shen DW, Fojo A, Chin JE, Roninson IB, Richert NPastan I, et al. Human multidrug-resistant cell lines: increased mdr1 expression can precede gene amplification. Science. 1986;232:643\u201345.","DOI":"10.1126\/science.3457471"},{"key":"795_CR17","doi-asserted-by":"crossref","unstructured":"Parekh H, Wiesen K, Simpkins H. Acquisition of taxol resistance via P-glycoprotein- and non-P-glycoprotein-mediated mechanisms in human ovarian carcinoma cells. Biochem Pharmacol. 1997;53:461\u201370.","DOI":"10.1016\/S0006-2952(97)83383-7"},{"key":"795_CR18","doi-asserted-by":"crossref","unstructured":"Wang YC, Juric D, Francisco B, Yu R, Pavlin MRen X, et al. Regional activation of chromosomal arm 7q with and without gene amplification in taxane-selected human ovarian cancer cell lines. Genes Chromosomes Cancer. 2006;45:365\u201374.","DOI":"10.1002\/gcc.20300"},{"key":"795_CR19","doi-asserted-by":"crossref","unstructured":"Lawlor D, Martin P, Busschots S, Thibault B, O\u2019Leary JJ, Stordal B. PARP inhibitors as P-glycoprotein substrates. J Pharm Sci. 2014;103:1913\u201320.","DOI":"10.1002\/jps.23952"},{"key":"795_CR20","doi-asserted-by":"crossref","unstructured":"Rottenberg S, Jaspers JE, Kersbergen A, Van der Burg E, Nygren AOHZander SAL, et al. High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs. Proc Natl Acad Sci USA. 2008;105:17079\u201384.","DOI":"10.1073\/pnas.0806092105"},{"key":"795_CR21","doi-asserted-by":"crossref","unstructured":"Dumitriu IE, Voll RE, Kolowos W, Herrmann M, Nauck M, Kalden JR. UV irradiation inhibits ABC transporters via generation of ADP-ribose by concerted action of poly(ADP-ribose) polymerase-1 and glycohydrolase. Cell Death Differ. 2004;11:314\u201320.","DOI":"10.1038\/sj.cdd.4401348"},{"key":"795_CR22","doi-asserted-by":"crossref","unstructured":"Durmus S, Sparidans RW, van Esch A, Wagenaar E, Schinkel AH. Breast cancer resistance protein (BCRP\/ABCG2) and P-glycoprotein (P-GP\/ABCB1) restrict oral availability and brain accumulation of the PARP inhibitor rucaparib (AG-014699). Pharm Res. 2015;32:37\u201346.","DOI":"10.1007\/s11095-014-1442-z"},{"key":"795_CR23","doi-asserted-by":"crossref","unstructured":"Kerb R, Fux R, M\u00f6rike K, Kremsner PG, Gil JP. Pharmacogenetics of antimalarial drugs: effect on metabolism and transport. Lancet Infect Dis. 2009;9:760\u201374.","DOI":"10.1016\/S1473-3099(09)70320-2"},{"key":"795_CR24","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1097\/00008571-200110000-00006","volume":"11","author":"D Dai","year":"2001","unstructured":"Dai D, Zeldin DC, Blaisdell JA, Chanas B, Coulter SJGhanayem BI, et al. Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid. Pharmacogenetics. 2001;11:351\u201359.","journal-title":"Pharmacogenetics"},{"key":"795_CR25","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1016\/S0006-2952(02)01354-0","volume":"64","author":"JBS Bahadur","year":"2002","unstructured":"Bahadur JBS, Leathart EM, Mutch D, Mackenzie PI, Daly AK. CYP2C8 polymorphisms in caucasians and their relationship with paclitaxel 6\u03b1-hydroxylase activity in human liver microsomes. Biochem Pharmacol. 2002;64:1579\u201389.","journal-title":"Biochem Pharmacol"},{"key":"795_CR26","doi-asserted-by":"crossref","unstructured":"Bergmann H, Gr\u00e9en C, Brasch-Andersen C, S\u00f6rensen M, Jensen HK, Herrstedt J. Retrospective study of the impact of pharmacogenetic variants on paclitaxel toxicity and survival in patients with ovarian cancer. Eur J Clin Pharmacol. 2011;67:693\u2013700.","DOI":"10.1007\/s00228-011-1007-6"},{"key":"795_CR27","doi-asserted-by":"crossref","unstructured":"Henningsson S, Marsh WJ, Loos MO, Karlsson MO, Ashton M. Association of CYP2C8, CYP3A4, CYP3A5, and ABCB1 polymorphisms with the pharmacokinetics of paclitaxel. Clin Cancer Res. 2005;11:8097\u2013104.","DOI":"10.1158\/1078-0432.CCR-05-1152"},{"key":"795_CR28","doi-asserted-by":"crossref","unstructured":"Barbuti AM, Chen ZS. Paclitaxel through the ages of anticancer therapy: exploring its role in chemoresistance and radiation therapy. Cancers. 2015;7:2360\u201371.","DOI":"10.3390\/cancers7040897"},{"key":"795_CR29","doi-asserted-by":"crossref","unstructured":"Parker AL, Teo WS, McCarroll JA, Kavallaris M. An emerging role for tubulin isotypes in modulating cancer biology and chemotherapy resistance. Int J Mol Sci. 2017;18:1434.","DOI":"10.3390\/ijms18071434"},{"issue":"4","key":"795_CR30","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1038\/s41417-021-00396-4","volume":"30","author":"O Wattanathamsan","year":"2023","unstructured":"Wattanathamsan O, Pongrakhananon V. Post-translational modifications of tubulin: their role in cancers and the regulation of signaling molecules. Cancer Gene Ther. 2023;30(4):521\u201328.","journal-title":"Cancer Gene Ther"},{"key":"795_CR31","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.3390\/cancers11111786","volume":"11","author":"M Binju","year":"2019","unstructured":"Binju M, Amaya-Padilla MA, Wan G, Gunosewoyo H, Sethi G. Therapeutic inducers of apoptosis in ovarian cancer. Cancers. 2019;11:1786.","journal-title":"Cancers"},{"key":"795_CR32","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.3390\/cancers11111631","volume":"11","author":"LF Al-Alem","year":"2019","unstructured":"Al-Alem LF, Baker AT, Pandya UM, Cunningham KA, Miller PS. Understanding and targeting apoptotic pathways in ovarian cancer. Cancers. 2019;11:1631.","journal-title":"Cancers"},{"key":"795_CR33","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.3892\/ijo.2017.3914","volume":"50","author":"T Yokoyama","year":"2017","unstructured":"Yokoyama T, Kohn EC, Brill E, Lee JM. Apoptosis is augmented in high-grade serous ovarian cancer by the combined inhibition of bcl-2\/Bcl-xL and PARP. Int J Oncol. 2017;50:1064\u201374.","journal-title":"Int J Oncol"},{"key":"795_CR34","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1158\/1535-7163.MCT-11-0693","volume":"11","author":"M Wong","year":"2012","unstructured":"Wong M, Tan N, Zha J, Peale F, Fairbrother WJ. Navitoclax (ABT-263) reduces bcl-xL-mediated chemoresistance in ovarian cancer models. Mol Cancer Ther. 2012;11:1026\u201335.","journal-title":"Mol Cancer Ther"},{"key":"795_CR35","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1038\/s41698-019-0084-3","volume":"3","author":"R Ben-Hamo","year":"2019","unstructured":"Ben-Hamo R, Zilberberg A, Cohen H, Barash H, Lavi O, Segal E. Resistance to paclitaxel is associated with a variant of the gene BCL2 in multiple tumor types. Npj Precis Oncol. 2019;3:12.","journal-title":"Npj Precis Oncol"},{"key":"795_CR36","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/978-1-4939-9220-1_3","volume-title":"RNA interference and cancer therapy: methods and protocols","author":"Y Takei","year":"2019","unstructured":"Takei Y. siRNA-based drug targeting human bcl-XL against cancers. In: RNA interference and cancer therapy: methods and protocols. Humana Press; 2019. p. 31\u201340."},{"key":"795_CR37","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.3389\/fphar.2018.01260","volume":"9","author":"S Rezvantalab","year":"2018","unstructured":"Rezvantalab S, Drude NI, Moraveji MK, G\u00fcvener N, Koons EK, Lammers T. PLGA-based nanoparticles in cancer treatment. Front Pharmacol. 2018;9:1260.","journal-title":"Front Pharmacol"},{"key":"795_CR38","unstructured":"Sharma R, Bhawna K, Singh S, Gupta G, Kumar PK, R. Layered double hydroxide nanomaterials: biomedical applications, current status, and challenges. Nano Life. 2020;10:191\u2013219."},{"key":"795_CR39","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1208\/s12249-011-9636-8","volume":"12","author":"D Pandita","year":"2011","unstructured":"Pandita D, Ahuja A, Lather V, Dutta T. Development of lipid-based nanoparticles for enhancing the oral bioavailability of paclitaxel. AAPS pharmscitech. 2011;12:712\u201322.","journal-title":"AAPS pharmscitech"},{"key":"795_CR40","doi-asserted-by":"crossref","unstructured":"Jurj A, Braicu C, Pop LA, Tomuleasa C, Gherman CD, Berindan-Neagoe I. The new era of nanotechnology, an alternative to change cancer treatment. Drug Des devel ther. 2017;11:2871\u201390.","DOI":"10.2147\/DDDT.S142337"},{"key":"795_CR41","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.jconrel.2019.08.034","volume":"311","author":"AM Khalifa","year":"2019","unstructured":"Khalifa AM, Elsheikh MA, Khalifa AM, Sarhan HA. Current strategies for different paclitaxel-loaded nano-delivery systems towards therapeutic applications for ovarian carcinoma: a review article. J Control Release. 2019;311:125\u201337.","journal-title":"J Control Release"},{"key":"795_CR42","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s12951-018-0392-8","volume":"16","author":"JK Patra","year":"2018","unstructured":"Patra JK, Das G, Fraceto LF, Campos EVR, Rodriguez-Torres MP, Acosta-Torres LS. Nano-based drug delivery systems: recent developments and future prospects. J Nanobiotechnol. 2018;16:71.","journal-title":"J Nanobiotechnol"},{"key":"795_CR43","doi-asserted-by":"publisher","first-page":"103125","DOI":"10.1016\/j.jddst.2022.103125","volume":"68","author":"V Yakati","year":"2022","unstructured":"Yakati V, Vangala S, Madamsetty VS, Banerjee R, Moku G. Enhancing the anticancer effect of paclitaxel by using polymeric nanoparticles decorated with colorectal cancer targeting CPKSNNGVC-peptide. J Drug Deliv Sci Technol. 2022;68:103125.","journal-title":"J Drug Deliv Sci Technol"},{"key":"795_CR44","doi-asserted-by":"crossref","unstructured":"Zaman A, Das PK. Transferrin tethered fluorescent organic nanoparticles for receptor-mediated targeted delivery of paclitaxel to cancer cells. Chem-Asian J. 2025;e202500135.","DOI":"10.1002\/asia.202500135"},{"key":"795_CR45","doi-asserted-by":"crossref","unstructured":"Inaba H, Nagata M, Miyake KJ, Saito K, Nakamura Y. Cyclic tau-derived peptides for stabilization of microtubules. Polym J. 2020;52:1143\u201351.","DOI":"10.1038\/s41428-020-0356-3"},{"key":"795_CR46","doi-asserted-by":"crossref","unstructured":"Khwaja S, Kumar K, Das R, Negi AS. Microtubule-associated proteins as targets for anticancer drug development. Bioorg Chem. 2021;116:105320.","DOI":"10.1016\/j.bioorg.2021.105320"},{"key":"795_CR47","doi-asserted-by":"publisher","first-page":"2849","DOI":"10.1158\/1078-0432.CCR-06-3040","volume":"13","author":"KM Bhat","year":"2007","unstructured":"Bhat KM, Setaluri V. Microtubule-associated proteins as targets in cancer chemotherapy. Clin Cancer Res. 2007;13:2849\u201354.","journal-title":"Clin Cancer Res"},{"key":"795_CR48","doi-asserted-by":"crossref","unstructured":"Dumontet C, Jordan MA, Lee FF. Ixabepilone: targeting \u03b2III-tubulin expression in taxane-resistant malignancies. Mol Cancer Ther. 2009;8:17\u201325.","DOI":"10.1158\/1535-7163.MCT-08-0986"},{"key":"795_CR49","doi-asserted-by":"crossref","unstructured":"Inaba H. Construction of functional microtubules and artificial motile systems based on peptide design. Polym J. 2023;55:1261\u201374.","DOI":"10.1038\/s41428-023-00838-w"},{"key":"795_CR50","doi-asserted-by":"crossref","unstructured":"Kavallaris M. Microtubules and resistance to tubulin-binding agents. Nat Rev Cancer. 2020;10(3):194\u2013204.","DOI":"10.1038\/nrc2803"},{"key":"795_CR51","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1038\/s41420-021-00453-9","volume":"7","author":"O Wattanathamsan","year":"2021","unstructured":"Wattanathamsan O, Thararattanobon R, Rodsiri R, Chanvorachote P, Vinayanuwattikun C, Pongrakhananon V. Tubulin acetylation enhances lung cancer resistance to paclitaxel-induced cell death through mcl-1 stabilization. Cell Death Discov. 2021;7:67.","journal-title":"Cell Death Discov"},{"key":"795_CR52","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1007\/s12272-018-1038-y","volume":"41","author":"KA Min","year":"2018","unstructured":"Min KA, Maharjan P, Ham S, Shin MC. Pro-apoptotic peptides-based cancer therapies: challenges and strategies to enhance therapeutic efficacy. Arch. Pharm. Res. 2018;41:594\u2013616.","journal-title":"Arch. Pharm. Res"},{"key":"795_CR53","doi-asserted-by":"publisher","first-page":"110386","DOI":"10.1016\/j.msec.2019.110386","volume":"108","author":"Y Wu","year":"2020","unstructured":"Wu Y, Ge P, Xu W, Li M, Kang Q, Zhang X, Xie J. Cancer-targeted and intracellular delivery of bcl-2-converting peptide with functional macroporous silica nanoparticles for biosafe treatment. Mater Sci Eng: C. 2020;108:110386.","journal-title":"Mater Sci Eng: C"},{"key":"795_CR54","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1016\/j.nano.2018.03.010","volume":"14","author":"D Gupta","year":"2018","unstructured":"Gupta D, Kumar M, Tyagi P, Kapoor S, Tyagi A, Barman TK. Concomitant delivery of paclitaxel and NuBCP-9 peptide for synergistic enhancement of cancer therapy. Nanomedicine. 2018;14:1301\u201313.","journal-title":"Nanomedicine"},{"key":"795_CR55","doi-asserted-by":"publisher","first-page":"190","DOI":"10.3390\/polym12091906","volume":"12","author":"S Kang","year":"2020","unstructured":"Kang S, Lee S, Park S. iRGD peptide as a tumor-penetrating enhancer for tumor-targeted drug delivery. Polymers. 2020;12:190.","journal-title":"Polymers"},{"key":"795_CR56","doi-asserted-by":"publisher","first-page":"3768","DOI":"10.3390\/cancers16223768","volume":"16","author":"D Nikitovic","year":"2024","unstructured":"Nikitovic D, Kukovyakina E, Berdiaki A, Tzanakakis A, Luss A, Vlaskina E. Enhancing tumor-targeted therapy: the role of iRGD peptide in advanced drug delivery systems. Cancers. 2024;16:3768.","journal-title":"Cancers"},{"key":"795_CR57","doi-asserted-by":"publisher","first-page":"8543","DOI":"10.2147\/IJN.S219820","volume":"14","author":"Y Zhong","year":"2019","unstructured":"Zhong Y, Su T, Shi Q, Feng Y, Tao Z, Huang Q. Co-administration of iRGD enhances tumor-targeted delivery and anti-tumor effects of paclitaxel-loaded PLGA nanoparticles for colorectal cancer treatment. Int J Nanomed. 2019;14:8543\u201360.","journal-title":"Int J Nanomed"},{"key":"795_CR58","doi-asserted-by":"publisher","first-page":"46057","DOI":"10.1038\/srep46057","volume":"7","author":"J Zhang","year":"2017","unstructured":"Zhang J, Wang L, Chan HF, Xie W, Chen S, He C. Co-delivery of paclitaxel and tetrandrine via iRGD peptide conjugated lipid-polymer hybrid nanoparticles overcomes multidrug resistance in cancer cells. Sci Rep. 2017;7:46057.","journal-title":"Sci Rep"},{"key":"795_CR59","doi-asserted-by":"publisher","first-page":"5138","DOI":"10.1016\/j.biomaterials.2013.03.036","volume":"34","author":"G Gu","year":"2013","unstructured":"Gu G, Gao X, Hu Q, Kang T, Liu Z, Jiang M. The influence of the penetrating peptide iRGD on the effect of paclitaxel-loaded MT1-AF7p-conjugated nanoparticles on glioma cells. Biomaterials. 2013;34:5138\u201348.","journal-title":"Biomaterials"},{"key":"795_CR60","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/j.biopha.2017.10.135","volume":"97","author":"LO Monteiro","year":"2018","unstructured":"Monteiro LO, Fernandes RS, Oda CM, Rodrigues LR, Ferreira DC, Barata TS. Paclitaxel-loaded folate-coated long-circulating and pH-sensitive liposomes as a potential drug delivery system: a biodistribution study. Biomed Pharmacother. 2018;97:489\u201395.","journal-title":"Biomed Pharmacother"},{"key":"795_CR61","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/978-3-031-04544-8_4","volume-title":"Peptide therapeutics: fundamentals of design, development, and delivery","author":"SM Shi","year":"2022","unstructured":"Shi SM, Di L. Strategies to optimize peptide stability and prolong half-life. In: Peptide therapeutics: fundamentals of design, development, and delivery. Cham: Springer International Publishing; 2022. p. 163\u201382."},{"key":"795_CR62","doi-asserted-by":"crossref","unstructured":"Pei J, Gao X, Pan D, Hua Y, He J, Liu Z. Advances in the stability challenges of bioactive peptides and improvement strategies. Curr Res Food Sci. 2022;5:2162\u201370.","DOI":"10.1016\/j.crfs.2022.10.031"},{"key":"795_CR63","doi-asserted-by":"crossref","unstructured":"Manteghi R, Pallagi E, Olajos G, Cs\u00f3ka I. Pegylation and formulation strategy of anti-microbial peptide (AMP) according to the quality by design approach. Eur J Pharm Sci. 2020;144:105197.","DOI":"10.1016\/j.ejps.2019.105197"},{"key":"795_CR64","doi-asserted-by":"crossref","unstructured":"Chen J, Hu S, Sun M, Shi J, Zhang H, Yu H. Recent advances and clinical translation of liposomal delivery systems in cancer therapy. Eur J Pharm Sci. 2024;106688.","DOI":"10.1016\/j.ejps.2023.106688"},{"key":"795_CR65","doi-asserted-by":"crossref","unstructured":"Fu H, Shi K, Hu G, Yang Y, Kuang Q, Lu L, He Q. Tumor-targeted paclitaxel delivery and enhanced penetration using TAT-decorated liposomes comprising redox-responsive poly (ethylene glycol). J Pharm Sci. 2015;104(3):1160\u201373.","DOI":"10.1002\/jps.24291"},{"key":"795_CR66","doi-asserted-by":"crossref","unstructured":"Zare-Zardini H, Saberian E, Jen\u010da A, Ghanipour-Meybodi R, Petr\u00e1\u0161ov\u00e1 A, Jen\u010dov\u00e1 J. From defense to offense: antimicrobial peptides as promising therapeutics for cancer. Front Oncol. 2024;14:1463088.","DOI":"10.3389\/fonc.2024.1463088"},{"key":"795_CR67","doi-asserted-by":"crossref","unstructured":"Wang L, Wang N, Zhang W, Cheng X, Yan Z, Shao G, Fu C. Therapeutic peptides: current applications and future directions. Signal Transduct. Target. Ther. 2022;7(1):48.","DOI":"10.1038\/s41392-022-00904-4"},{"key":"795_CR68","doi-asserted-by":"crossref","unstructured":"Xiao Y, He Z, Li W, Chen D, Niu X, Yang X, Gao Y. A covalent peptide-based lysosome-targeting protein degradation platform for cancer immunotherapy. Nat Commun. 2025;16(1):1388.","DOI":"10.1038\/s41467-025-56648-6"}],"container-title":["Pharmacological Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43440-025-00795-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s43440-025-00795-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43440-025-00795-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T12:19:28Z","timestamp":1781612368000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s43440-025-00795-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,20]]},"references-count":68,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["795"],"URL":"https:\/\/doi.org\/10.1007\/s43440-025-00795-6","relation":{},"ISSN":["1734-1140","2299-5684"],"issn-type":[{"value":"1734-1140","type":"print"},{"value":"2299-5684","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,20]]},"assertion":[{"value":"27 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 October 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors have agreed to publish this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}